{
    "relation": [
        [
            "",
            "Total, other (not including serious) adverse events",
            "# participants affected / at risk",
            "Infections and infestations",
            "Bronchitis * 1",
            "# participants affected / at risk"
        ],
        [
            "Maraviroc",
            "",
            "4/79 (5.06%)",
            "",
            "",
            "4/79 (5.06%)"
        ]
    ],
    "pageTitle": "Non-Interventional Study Of Celsentri\u00ae In Treatment Experienced Patients With CCR5-Tropic HIV-Infection - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00850395?sect=X40156&view=results",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042981856.5/warc/CC-MAIN-20150728002301-00058-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 860525267,
    "recordOffset": 860509329,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Participant Flow: \u00a0 Overall Study Participants who were prescribed maraviroc tablets orally in accordance with Summary of Product Characteristics (SmPC) were observed for a period of up to 12 months or early discontinuation. Maraviroc Description \u00a0 Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: maraviroc Intervention: HIV-1 Condition:",
    "textAfterTable": "Insufficient clinical response \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 3 \u00a0 Unspecified \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 5 \u00a0 \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered. Reporting Groups \u00a0 Description Maraviroc Participants who were prescribed maraviroc tablets orally in accordance with Summary of Product Characteristics (SmPC) were observed for a period of up to 12 months or early discontinuation. Baseline Measures",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}